Skip to main content
OpenTrials
Completed

NCT Number: NCT03111927

Infant Nutrition and Brain Development

Research study on the role of early life nutrition on brain and cognitive development during infancy and early childhood. Two blends of myelin-relevant nutrients at different levels were compared and a breastfed group was considered as epidemiological reference.

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 week–6 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States

Loading trial locations.

About this study

This nutritional intervention study involved assessments in both the mother and her infant. The mother was asked to complete self-report questionnaires and to undergo a brief cognitive assessment. If the mother was not breastfeeding, a study product was provided and was consumed by the infant daily up to 12 months of life. The study also involved magnetic resonance imaging (MRI) brain scans of the infant's brain while asleep as well as evaluation of cognitive outcomes, including general cognitive development, and social-emotional development.

Once all trial subjects completed the 6-month timepoint (intervention part), an inferential statistical analysis of all data up to 6 months was performed.

Product codes (blinding) were broken to compare groups and an appropriate operational framework was put in place to maintain the individual assignment unknown to the Sponsor and Sites until the end of the trial.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Term infants (≥ 37 weeks)
  • Neuro typical development
  • No major risk factors for learning, neurologic, or psychiatric disorder
  • Between 2 weeks and maximum 5 weeks of age. If mother is breastfeeding she can choose the infant begin the trial prior 2 weeks.
  • Parents/legal guardians willing and able to complete the informed consent process

Exclusion criteria

  • Delayed birth (> 41 weeks gestation)
  • Birth Weight < 2000 g or small for gestation age or large for gestational age
  • Psychopharmacological treatment of mother using prohibited medications during pregnancy
  • In utero exposure to alcohol abuse or illicit substances as per the American College of Obstetricians and Gynecologists
  • Abnormalities on fetal ultrasound
  • Complicated pregnancy
  • Neonatal intensive care unit admission and/or emergency surgical delivery

Treatment and study plan

Infant Formula: enriched level of myelin-relevant nutrients

Other

Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).

The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months.

Other names: Infant Formula

Infant formula: standard level of myelin-relevant nutrients

Other

Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).

The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months.

Other names: Infant Formula

Primary outcomes

  1. Brain structural connectivity

    Time frame: 3, 6, 12, 18, and 24 months of life

    Longitudinal analysis de novo myelination and comparison between the 3 study arms De novo myelination being assessed by brain magnetic resonance imaging (MRI; multicomponent relaxometry). [Physiological marker, MRI].

  2. Brain functional connectivity

    Time frame: 3, 6, 12, 18, and 24 months of life

    Cross-sectional analysis de novo myelination and comparison between the 3 study arms De novo myelination being assessed by brain magnetic resonance imaging (MRI; multicomponent relaxometry). [Physiological marker, MRI].

  3. Brain De novo myelination

    Time frame: 3, 6, 12, 18, and 24 months of life

    Brain magnetic resonance imaging (MRI) derived measures (volumetric anatomical imaging) [Physiological marker, MRI].

  4. Infant Cognitive Development

    Time frame: 6, 12, and 24 months of life

    Standardized neurodevelopment test.

  5. Infant Early Learning Assessment

    Time frame: 18 and 24 months of life

    Computer-based cognitive tasks.

  6. Infant Social Emotional Development

    Time frame: 3, 6, 12, 18, and 24 months of life

    Parent report questionnaire.

Secondary outcomes

  1. Infant dietary assessment

    Time frame: 6, 9, 12, 18, and 24 months of life

    Three days food records are planned at the specified time-frames.

  2. Breast milk nutrients profile

    Time frame: week 3, week 6, and 3 months of life

    Nutrients (vitamins, minerals, and other nutrients) levels analyses in breast milk nutrients (subsample) [Physiological parameter].

  3. Brain structure

    Time frame: 3, 6, 12, 18, and 24 months of life

    MRI

  4. Blood nutrients profile (optional)

    Time frame: 6, 12, and 24 months of life

    Nutrients (vitamins, minerals, and other nutrients) levels

  5. Sleep

    Time frame: 3, 6, 12, 18, and 24 months of life

    Questionnaire

Sponsors and collaborators

Lead sponsor

Société des Produits Nestlé (SPN)

Industry

Registry information

Official study title

The Effect of Myelin-Relevant Nutrients in Infant Formula on Brain Myelination and Cognitive Development

Important dates

Study start
2017
Primary completion
2021
Study completion
2022
First posted
Apr 13, 2017
Registry last updated
Jul 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.